OEL Fastrac Catalog

Quercetin 3-O-glucopyranoside (also known as isoquercitrin and isoquercetin) is a quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. It belongs to the class of organic compounds known as flavonoid-3-o-glycosides. It is a quercetin O-glucoside, a tetrahydroxyflavone, a beta-D-glucoside and a monosaccharide derivative. It derives from a beta-D-glucose. Isolated from Lepisorus contortus, it exhibits antineoplastic activity and has been found to decrease the rate of polymerization and sickling of red blood cells. Isoquercetin has a role as an antineoplastic agent, a plant metabolite, a bone-density conservation agent, an osteogenesis regulator, an antioxidant, a histamine antagonist and an antipruritic drug. Isoquercetin has been used in clinical trials studying the treatment of kidney cancer, renal cell carcinoma, advanced renal cell carcinoma, venous thromboembolism (VTE) in pancreatic cancer, and venous thromboembolism (VTE) in colorectal cancer, among others. Isoquercitrin, in combination with masitinib, is under investigation in clinical trials for best supportive care in hospitalized patients with moderate and severe coronavirus disease 2019 (COVID-19).

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Please note: Due to the complexity and amount of studies regarding this compound—a Natural Health Product—increased cost is charged.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Quercetin 3-O-glucopyranoside, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.